OracleBio will be attending the 3rd Annual NASH Summit 2019, which takes place from the 22nd to 25th of April in Boston, MA, USA.
OracleBio is a leading digital pathology service provider with in-depth expertise in supporting NASH/NAFLD & Fibrosis research. Utilising Visiopharm Oncotopix and Indica Labs Halo image analysis software, we provide detailed quantification of cells and biomarkers in liver tissue including immune/inflammatory cell count, collagen levels, vacuole content and fibrotic lesion area in stained histology / IHC tissue slides. We deliver cell-by-cell data for improved study interpretation and decision making in preclinical and clinical R&D. Click here to find out more information about how our services can support your NASH research.
The 3rd Annual NASH Summit 2019 program will cover every element of NASH drug development from early discovery to late-stage clinical development and commercialization. The NASH Summit is the industry’s most comprehensive forum for advancing the development of successful NASH therapeutics. Focused on discovery through to late-stage clinical development of non-alcoholic steatohepatitis (NASH) candidate pipelines, the 3rd Annual NASH Summit Boston will bring together 300+ drug developers from 140+ organizations across 4 days of unparalleled content sharing and networking. To find out more about the 3rd Annual NASH Summit, please click here.
Lorcan Sherry, OracleBio’s CSO, along with our Business Development Assistant, Alison Stewart, will be in attendance for the summit.
If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with our team during the event, please contact us.